Q1 2026: Revenue Holds Steady While Profitability Remains Tight

Strata Critical Medical (SRTA) opened 2026 with Q1 revenue of US$67.4 million and basic EPS of US$0.03, alongside net income from ongoing operations of US$2.4 million. This set a mixed tone for the latest update. The company has seen quarterly revenue move from US$36.4 million in Q4 2024 to US$67.4 million in Q1 2026. Basic EPS has ranged from a loss of US$0.09 in Q4 2024 to a profit of US$0.03 in the latest quarter, highlighting a business that is growing its top line while still working through a volatile earnings profile and tight margins.

See our full analysis for Strata Critical Medical.

With the headline numbers on the table, the next step is to set these results against the most common narratives around Strata Critical Medical to see which storylines hold up and where the margin picture tells a different story.

TTM loss of US$16.1 million keeps profitability in focus

• On a trailing 12 month basis to Q1 2026, Strata Critical Medical recorded total revenue of US$228.6 million and a net loss from ongoing operations of US$16.1 million, with basic EPS at a loss of US$0.19 over the same period.
• Consensus narrative expects sustained growth in medical air transport to support margin progress over time. However, the current 12 month loss of US$16.1 million and the mix of profitable quarters like Q1 2026 alongside several loss making periods in 2025 show that earnings are still uneven, which means investors relying on the consensus view need to watch how consistently margins track the revenue trend rather than assuming a smooth path.
  • The quarterly pattern, from a loss of US$9.7 million in Q3 2025 and US$7.4 million in Q4 2024 to a profit of US$2.4 million in Q1 2026, illustrates how operating leverage can swing results while the business scales.
  • With analysts not expecting profitability over the next three years and basic EPS running at a loss of US$0.19 over the last 12 months, the current data points indicate that any growth led thesis needs to account for a period of continued earnings pressure.

Revenue growth forecasts meet widening multi year losses

• Revenue is forecast to grow at about 13.65% per year, ahead of the 11.3% forecast for the US market, while losses have grown at roughly 6.6% per year over the past five years and the trailing 12 month net loss sits at US$16.1 million.
• Bulls argue that a recession resistant medical transport focus and a sizeable cash position can support long term earnings growth. At the same time, the combination of a 13.65% revenue growth forecast alongside a five year record of rising losses and an expected three more years without profitability means the bullish view depends on a clear inflection in how each extra dollar of revenue converts to profit.
  • The shift from quarterly losses in 2025, such as US$5.4 million in Q4, to a profit of US$2.4 million in Q1 2026 shows that operating results can improve, but the trailing 12 month loss highlights that one better quarter does not yet change the overall earnings run rate.
  • Because losses have increased over several years even as revenue has expanded, any bullish case based on scale benefits needs to be checked against how future quarters compare to the current trailing 12 month loss and whether that 6.6% annual loss growth pattern starts to flatten out.

Do bulls have the growth story right when losses are still building in the background, or is the market underpricing a potential earnings turn for a focused medical transport business that reported a profitable quarter in Q1 2026, while forecasts still call for three more years of losses and revenue is expected to grow around 13.65% per year against a US$16.1 million trailing 12 month loss and a five year record of losses rising 6.6% a year, leaving room for upside if margins start to catch up to the top line or disappointment if they do not, according to bullish investors who see resilience in this niche. 🐂 Strata Critical Medical Bull Case

Valuation tension between P/S premium and DCF gap

• At a share price of US$5.33, Strata Critical Medical trades on a P/S of 2.3x, above both the US Healthcare industry at 1.2x and peers at 1.4x, while the DCF fair value is US$12.77 and the analyst consensus price target is US$8.81.
• Bears highlight that paying a P/S premium for an unprofitable business with growing multi year losses is risky, and the current 2.3x multiple against an industry 1.2x and peer 1.4x supports that concern, even though the DCF fair value of US$12.77 and a consensus target of US$8.81 both sit above the current US$5.33 price. This creates a clear split between cash flow based and multiples based views.
  • The roughly 58% gap between the current price of US$5.33 and the DCF fair value of US$12.77 indicates that one set of investors sees meaningful upside, while the P/S premium suggests that others are already paying up for growth despite continued losses.
  • Because the company is not forecast to be profitable over the next three years and the trailing 12 month result is still a US$16.1 million loss, skeptics viewing the 2.3x P/S as expensive relative to unprofitable peers can point to the earnings record as a reason the market might continue to discount the stock compared with model based fair values.

With losses still in the trailing 12 month numbers and the stock already trading at a higher P/S than the wider healthcare group, skeptics argue that the current price leaves limited room for further disappointment even though DCF and target prices sit higher on paper. 🐻 Strata Critical Medical Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Strata Critical Medical on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With bulls and bears clearly split on the story so far, it makes sense to move quickly, review the data yourself and decide where you stand, then weigh up the 2 key rewards and 1 important warning sign.

Explore Alternatives

Strata Critical Medical combines a trailing 12 month loss of US$16.1 million, uneven quarterly earnings and a P/S premium to its healthcare peers.

If that mix of ongoing losses and a richer valuation does not quite fit your risk comfort, it is worth scanning the 74 resilient stocks with low risk scores for ideas with steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.